HONG KONG – Aslan Pharmaceuticals Pte Ltd., an oncology-focused biotech company headquartered in Singapore, is set to commence a global pivotal study to treat biliary tract cancer with its lead product, varlitinib (ASLAN-001), after getting clearance from the FDA.